LAPTM4B-35 Overexpression is an independent prognostic marker in endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 745-750

  Meng, Fan Ling ^a   Yin, Ming Zhu ^a   Song, Hong Tao ^b   Yang, Hua ^c   Lou, Ge ^a,b   Zhou, Rou Li ^c  

^a Departments of Gynecology   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Endometrial carcinoma; Immunohistochemistry; Lysosomal protein transmembrane 4 ; Prognosis

Indexed keywords

LYSOSOMAL PROTEIN TRANSMEMBRANE 4 A 35; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; ONCOGENE PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 77956808753     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181e02f90     Document Type: Article

References (20)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8Y31, 1.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10Y30.
3. Fowler W, Mutch D. Management of endometrial cancer. Womens Health (Lond). 2008;4:479Y489.
4. Garg K, Leitao MM Jr,Wynveen CA, et al. p53 Overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 2010;23:80Y92.
5. Konstantinova D, Kaneva R, Dimitrov R, et al. Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer. DNA Cell Biol. 2010;29:65Y70.
6. Lambropoulou M, Papadopoulos N, Tripsianis G, et al. Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): Prognostic value and survival of endometrial cancer patients. J Cancer Res Clin Oncol. 2010;136:427Y435.
7. Shao GZ, Zhou RL, Zhang QY, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003;22:5060Y5069.
8. Liu XR, Zhou RL, Zhang QY, et al. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol. 2004;10:1555Y1559.
9. Peng C, Zhou RL, Shao GZ, et al. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol. 2005;11: 2704Y2708.
10. Zhou L, He XD, Chen J, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007;43:809Y815.
11. Yang Y, Yang H, McNutt MA, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep. 2008;20:1077Y1083.
12. Yang H, Xiong FX, Lin M, et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:275Y281.
13. Zhou L, He XD, Cui QC, et al. Expression of LAPTM4B-35: A novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 2008;264:209Y217.
14. He J, Shao G, Zhou R. Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells [in Chinese]. Beijing Da Xue Xue Bao. 2003;35:348Y352.
15. Liu X, Zhou R, Zhang Q, et al. Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene [in Chinese]. Beijing Da Xue Xue Bao. 2003;35:340Y347.
16. Zhou L, He XD, Yu J, et al. Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg. 2010;199:515Y521.
17. Liu X, Xiong F, Wei X, et al. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci. 2009;100:2335Y2340.
18. Liu J, Zhou R, Zhang N, et al. Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl). 2000;113:881Y885.
19. Cabrita MA, Hobman TC, Hogue DL, et al. Mouse transporter protein, a membrane protein that regulates cellular multidrug resistance, is localized to lysosomes. Cancer Res. 1999;59: 4890Y4897.
20. Kasper G, Vogel A, Klaman I, et al. The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett. 2005;224:93Y103.